
Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Nomlabofusp
Therapeutic Area : Genetic Disease
Study Phase : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Larimar Doses Adolescents in Nomlabofusp Pharmacokinetic Study in Friedreich’s Ataxia
Details : CTI-1601 (nomlabofusp) is a recombinant fusion protein intended to deliver human frataxin to the mitochondria of patients with Friedreich’s ataxia who cannot produce enough of this essential protein.
Product Name : Undisclosed
Product Type : Protein
Upfront Cash : Inapplicable
January 23, 2025
Lead Product(s) : Nomlabofusp
Therapeutic Area : Genetic Disease
Highest Development Status : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Nomlabofusp
Therapeutic Area : Genetic Disease
Study Phase : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
A Study to Assess Nomlabofusp in Adolescents and Children with Friedreich's Ataxia
Details : Nomlabofusp is a Protein drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Friedreich Ataxia.
Product Name : Undisclosed
Product Type : Protein
Upfront Cash : Inapplicable
November 08, 2024
Lead Product(s) : Nomlabofusp
Therapeutic Area : Genetic Disease
Highest Development Status : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : CTI-1601
Therapeutic Area : Genetic Disease
Study Phase : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
An Open Label Extension Study of CTI-1601 in Subjects With Friedreich's Ataxia
Details : CTI-1601 is a Protein drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Friedreich Ataxia.
Product Name : Undisclosed
Product Type : Protein
Upfront Cash : Inapplicable
June 06, 2024
Lead Product(s) : CTI-1601
Therapeutic Area : Genetic Disease
Highest Development Status : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Nomlabofusp
Therapeutic Area : Genetic Disease
Study Phase : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Larimar Selected by FDA for START Program for Nomlabofusp in Friedreich's Ataxia
Details : CTI-1601 (nomlabofusp) is a recombinant fusion protein intended to deliver human frataxin to the mitochondria of patients with Friedreich’s ataxia who cannot produce enough of this essential protein.
Product Name : Undisclosed
Product Type : Protein
Upfront Cash : Inapplicable
May 30, 2024
Lead Product(s) : Nomlabofusp
Therapeutic Area : Genetic Disease
Highest Development Status : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Nomlabofusp
Therapeutic Area : Genetic Disease
Study Phase : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Larimar: FDA Removes Partial Hold on Nomlabofusp Friedreich's Program
Details : CTI-1601 (nomlabofusp) is a recombinant fusion protein intended to deliver human frataxin to the mitochondria of patients. It is being developed for the treatment of Friedreich’s Ataxia.
Product Name : Undisclosed
Product Type : Protein
Upfront Cash : Inapplicable
May 20, 2024
Lead Product(s) : Nomlabofusp
Therapeutic Area : Genetic Disease
Highest Development Status : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Nomlabofusp
Therapeutic Area : Genetic Disease
Study Phase : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Larimar Doses First Patient in Extension Study for Nomlabofusp in Friedreich's Ataxia
Details : CTI-1601 (nomlabofusp) is a recombinant fusion protein intended to deliver human frataxin to the mitochondria of patients. It is being developed for the treatment of Friedreich’s Ataxia.
Product Name : Undisclosed
Product Type : Protein
Upfront Cash : Inapplicable
March 11, 2024
Lead Product(s) : Nomlabofusp
Therapeutic Area : Genetic Disease
Highest Development Status : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Nomlabofusp
Therapeutic Area : Genetic Disease
Study Phase : Phase II
Sponsor : Leerink Partners
Deal Size : $172.5 million
Deal Type : Public Offering
Larimar Therapeutics Announces Closing of Public Offering and Full Exercise of Option
Details : Larimar intends to use the net proceeds from the proposed offering to support the development of CTI-1601 (nomlabofusp), a recombinant fusion protein, for the treatment for Friedreich’s ataxia.
Product Name : Undisclosed
Product Type : Protein
Upfront Cash : Undisclosed
February 16, 2024
Lead Product(s) : Nomlabofusp
Therapeutic Area : Genetic Disease
Highest Development Status : Phase II
Sponsor : Leerink Partners
Deal Size : $172.5 million
Deal Type : Public Offering

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Nomlabofusp
Therapeutic Area : Genetic Disease
Study Phase : Phase II
Sponsor : Leerink Partners
Deal Size : $150.0 million
Deal Type : Public Offering
Larimar Therapeutics Announces Pricing of Underwritten Public Offering of Common Stock
Details : Larimar intends to use the net proceeds from the proposed offering to support the development of CTI-1601 (nomlabofusp), a recombinant fusion protein, for the treatment for Friedreich’s ataxia.
Product Name : Undisclosed
Product Type : Protein
Upfront Cash : Undisclosed
February 14, 2024
Lead Product(s) : Nomlabofusp
Therapeutic Area : Genetic Disease
Highest Development Status : Phase II
Sponsor : Leerink Partners
Deal Size : $150.0 million
Deal Type : Public Offering

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Nomlabofusp
Therapeutic Area : Genetic Disease
Study Phase : Phase II
Sponsor : Leerink Partners
Deal Size : Undisclosed
Deal Type : Public Offering
Larimar Therapeutics Announces Proposed Underwritten Public Offering
Details : Larimar plans to support the development of CTI-1601 (nomlabofusp), a recombinant fusion protein delivering human frataxin for Friedreich's ataxia, alongside other pipeline candidates.
Product Name : Undisclosed
Product Type : Protein
Upfront Cash : Undisclosed
February 13, 2024
Lead Product(s) : Nomlabofusp
Therapeutic Area : Genetic Disease
Highest Development Status : Phase II
Sponsor : Leerink Partners
Deal Size : Undisclosed
Deal Type : Public Offering

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Nomlabofusp
Therapeutic Area : Genetic Disease
Study Phase : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Larimar Reports Positive Top-Line Data from Phase 2 of Nomlabofusp in Friedreich’s Ataxia
Details : CTI-1601 (nomlabofusp) is a recombinant fusion protein intended to deliver human frataxin to the mitochondria of patients. It is being developed for the treatment of Friedreich’s Ataxia.
Product Name : Undisclosed
Product Type : Protein
Upfront Cash : Inapplicable
February 12, 2024
Lead Product(s) : Nomlabofusp
Therapeutic Area : Genetic Disease
Highest Development Status : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
